Literature DB >> 12582292

A clinical pathway for pediatric gastroenteritis.

Susan Jones1.   

Abstract

Gastroenteritis is one of the most common reasons for hospitalization in the United States for children under the age of 5 years. Second only to respiratory problems, the cost of providing care for these children is estimated to exceed $2 billion dollars annually ( Burkhart, 1999; Prescilla, 2002). This article reviews the causes of gastroenteritis as well as the 1996 American Academy of Pediatrics Guidelines for treatment of gastroenteritis. These guidelines and more recently published literature were used to develop a clinical pathway to improve the care of pediatric patients admitted to the hospital with gastroenteritis. The article discusses the importance of clinical pathways and the process of implementation of a pathway for pediatric gastroenteritis. Additionally, the article provides a parent teaching tool to address recurrent questions parents have related to home management of a child with gastroenteritis. Useful web sites for resource information related to gastroenteritis are provided as well.

Entities:  

Mesh:

Year:  2003        PMID: 12582292     DOI: 10.1097/00001610-200301000-00003

Source DB:  PubMed          Journal:  Gastroenterol Nurs        ISSN: 1042-895X            Impact factor:   0.978


  3 in total

1.  Standardized Clinical Pathways for Hospitalized Children and Outcomes.

Authors:  K Casey Lion; Davene R Wright; Suzanne Spencer; Chuan Zhou; Mark Del Beccaro; Rita Mangione-Smith
Journal:  Pediatrics       Date:  2016-03-21       Impact factor: 7.124

2.  Epidemiological studies on gastroenteritis in children in the Bannu district, Khyber Pakhtunkhwa, Pakistan.

Authors:  Muhammad Ashraf Khan
Journal:  Z Gesundh Wiss       Date:  2021-05-21

3.  Epidemiology of Human Adenovirus in Pakistani Children Hospitalized with Community-Acquired Gastroenteritis under the Age of Five Years.

Authors:  Nazif Ullah Khan; Aamer Ali Shah; Syed Sohail Zahoor Zaidi; Zhi Chen
Journal:  Int J Environ Res Public Health       Date:  2022-10-01       Impact factor: 4.614

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.